Nicotine Addiction
Cigarettes are just the deadliest delivery vehicle. 8.7 million people a year die mostly from the smoke, but nicotine is the chemical that keeps them lighting up, and the industry has spent a century engineering products, cigarettes, then vapes, then pouches, to maximize exactly that addiction. Effective treatment exists. Access is the barrier.
Global mortality from preventable causes.
Tobacco kills 8+ million annually worldwide.
Most of the disease burden from smoking comes from the tar and combustion byproducts in smoke, not the nicotine itself. But nicotine is what keeps people smoking despite knowing exactly what it costs them: dependence researchers rank it alongside heroin and cocaine for how hard it is to quit. Treat cigarettes as one delivery vehicle for an addictive chemical, not the problem in isolation, and the real target comes into focus.
As cigarette sales decline, the same companies moved straight into other nicotine formats. Philip Morris International bought Swedish Match, maker of Zyn nicotine pouches, for roughly $16 billion in 2022. Altria took a multibillion-dollar stake in Juul. British American Tobacco owns Vuse vapes and Velo pouches. The business was never tobacco specifically, it was nicotine addiction, and it followed the customer to whatever product delivers it next.
Smoking-related disease kills an estimated 8.7 million people per year worldwide. It destroys families, reduces productivity, and drives healthcare costs. Traditional cessation methods (nicotine replacement, behavioral therapy) have modest success rates precisely because they're fighting a dependence, not a bad habit.
Science has discovered interventions that work on the addiction itself. Psilocybin-assisted therapy for smoking cessation has achieved success rates that dwarf conventional approaches. Yet regulatory barriers keep this treatment from most people who need it.
A 2023 Johns Hopkins study showed 80% of heavy smokers quit after psilocybin-assisted therapy. This compares to 35% with varenicline (best pharmaceutical) and 15% with placebo. The effect is not marginal - it is transformative.
Psilocybin appears to increase neuroplasticity and reduce default mode network activity. This allows smokers to disrupt entrenched neural patterns and reconstruct their relationship with nicotine. The mechanism is psychological and neurobiological.
Psilocybin remains Schedule I in most jurisdictions, blocking research and clinical deployment. This regulatory barrier keeps life-saving treatment from millions. Change requires evidence-based policy reform - not stigma-based prohibition.
Olfactory conditioning during sleep pairs nicotine smell with aversive stimuli (like rotten egg odor) to create negative association. This behavioral approach leverages classical conditioning to disrupt smoking behavior. The technique is non-invasive and accessible, making it a practical complement to pharmacological treatments.
Phase 1: Make psilocybin-assisted therapy available everywhere. 80% success rate vs 35% pharmaceuticals. Support clinical trials and policy reform. Phase 2: Regulate nicotine addiction across every delivery format, cigarettes, vapes, and pouches alike, instead of chasing whichever product the industry is currently pivoting to. Tax it. Ban advertising. Support people in quitting via proven methods. Phase 3: Hold the companies accountable for the addiction they engineer, not just the product category they're selling it in this decade.
Anyone can propose a solution. The community votes on the most impactful ideas.
Loading solutions...
Approved companies and organizations addressing this problem. Anyone can submit one for review.
A direct-action shareholder activist group that targets tobacco companies the way Sea Shepherd targets whaling fleets: buying stock to force votes, funding lawsuits, and publicly disrupting investor meetings until staying in the tobacco business costs more than leaving it.
